0001209191-24-001155.txt : 20240108
0001209191-24-001155.hdr.sgml : 20240108
20240108164346
ACCESSION NUMBER: 0001209191-24-001155
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231104
FILED AS OF DATE: 20240108
DATE AS OF CHANGE: 20240108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Regnante Keith
CENTRAL INDEX KEY: 0001682068
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 24520742
MAIL ADDRESS:
STREET 1: 733 CONCORD AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811173868
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-314-6297
MAIL ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-04
0
0001664710
Keros Therapeutics, Inc.
KROS
0001682068
Regnante Keith
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
LEXINGTON
MA
02421
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-11-04
4
M
0
40000
16.00
A
40000
D
Common Stock
2023-11-04
4
S
0
40000
45.29
D
0
D
Employee Stock Option (right to buy)
16.00
2024-01-04
4
M
0
40000
0.00
D
2030-04-06
Common Stock
40000
53622
D
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante
2024-01-08